All In Biotech

Free tool

FAERS Monitor: Camcevi Kit

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 211488 or its brand name (Camcevi Kit, Leuprolide Mesylate). Reports on generic versions are filed under their own applications.

Reports

1,595

Serious

1,120

70% of reports

Hospitalization

522

Death reported

132

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective118
  • fatigue99
  • off label use90
  • nausea79
  • headache69
  • malignant neoplasm progression62
  • disease progression57
  • vomiting49
  • febrile neutropenia48
  • product storage error45
  • hot flush44
  • product use in unapproved indication41
  • anaemia39
  • dyspnoea39
  • pain39

Reports by year received

View as table
YearReports
20052
20063
20116
20127
201327
201431
201531
201630
201762
201894
2019151
2020126
2021140
2022126
2023140
2024159
2025250
2026210

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,564 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
febrile neutropeniaSignal489.57.2360
malignant neoplasm progressionSignal628.06.3374
hot flushSignal447.75.8251
product storage errorSignal456.85.1217
disease progressionSignal576.44.9253
anaemiaSignal392.72.040
product use in unapproved indicationSignal412.21.625
fatigue991.71.427
headache691.51.210
vomiting491.41.05
off label use901.41.18
nausea791.31.16
drug ineffective1181.21.03
dyspnoea390.90.70
pain390.80.61

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.